Lumos Diagnostics announced changes to the management team with the appointment of current Executive Chair Sam Lanyon as Interim CEO. Following a review of Lumos' operations, Sam will lead the company whilst the executive search process for a new CEO, which is already in process, is completed. Rob Sambursky has transitioned to the role of Chief Medical Officer in which he will focus on Lumos' clinical affairs and support for the Company's commercial operations.
Lumos Diagnostics Holdings Limited
Equities
LDX
AU0000157091
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.038 AUD | -2.56% | -19.15% | -47.95% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-47.95% | 12.46M | |
-5.86% | 12.09B | |
-3.26% | 8.21B | |
+5.47% | 5.74B | |
+29.74% | 5.64B | |
-9.89% | 4.16B | |
-57.92% | 2.88B | |
+11.87% | 2.69B | |
-5.19% | 2.33B | |
+23.62% | 2.17B |
- Stock Market
- Equities
- LDX Stock
- News Lumos Diagnostics Holdings Limited
- Lumos Diagnostics Announces Appointment of Current Executive Chair Sam Lanyon as Interim CEO